Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus...

Full description

Saved in:
Bibliographic Details
Main Authors: Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, Crystal M. Richardson, Sayeh Agah, Anna Pomés, Peter M. Kasson, Mark A. Tomai, Christopher B. Fox, William A. Petri
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c2
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items